adjuvant chemotherapy

Summary

Summary: Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.

Top Publications

  1. ncbi Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy
    Dawn Hershman
    Department of Medicine and Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    J Natl Cancer Inst 99:196-205. 2007
  2. ncbi Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer
    Rodrigo Arriagada
    Instituto de Radiomedicina, Santiago, Chile
    N Engl J Med 350:351-60. 2004
  3. ncbi Gene expression profiling predicts clinical outcome of breast cancer
    Laura J van 't Veer
    Division of Diagnostic Oncology, The Netherlands Cancer Institute, 121 Plesmanlaan, 1066 CX Amsterdam, The Netherlands
    Nature 415:530-6. 2002
  4. ncbi DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy
    Ken A Olaussen
    Laboratory of Radiobiology and Oncology, Commissariat a l Energie Atomique, Fontenay aux Roses, University of Paris 11, Paris, France
    N Engl J Med 355:983-91. 2006
  5. ncbi Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Edward H Romond
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    N Engl J Med 353:1673-84. 2005
  6. ncbi Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18
    B Fisher
    Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Shadyside Hospital, PA, USA
    J Clin Oncol 15:2483-93. 1997
  7. ncbi Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer
    Timothy Winton
    National Cancer Institute of Canada Clinical Trials Group, Kingston, Ont
    N Engl J Med 352:2589-97. 2005
  8. ncbi Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis
    Val Gebski
    National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia
    Lancet Oncol 8:226-34. 2007
  9. doi Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial
    Thierry Andre
    Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, Paris 75012, France
    J Clin Oncol 27:3109-16. 2009
  10. ncbi Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial
    Joseph Ragaz
    McGill University Health Center, Royal Victoria Hospital, 687 Pine Ave, Montreal, PQ, Canada H3A 1A1
    J Natl Cancer Inst 97:116-26. 2005

Detail Information

Publications349 found, 100 shown here

  1. ncbi Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy
    Dawn Hershman
    Department of Medicine and Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    J Natl Cancer Inst 99:196-205. 2007
    Recently, increasing numbers of women receiving adjuvant chemotherapy for breast cancer have also received granulocyte colony-stimulating factors (G-CSFs) or granulocyte-macrophage colony-stimulating factors (GM-CSFs)...
  2. ncbi Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer
    Rodrigo Arriagada
    Instituto de Radiomedicina, Santiago, Chile
    N Engl J Med 350:351-60. 2004
    On the basis of a previous meta-analysis, the International Adjuvant Lung Cancer Trial was designed to evaluate the effect of cisplatin-based adjuvant chemotherapy on survival after complete resection of non-small-cell lung cancer.
  3. ncbi Gene expression profiling predicts clinical outcome of breast cancer
    Laura J van 't Veer
    Division of Diagnostic Oncology, The Netherlands Cancer Institute, 121 Plesmanlaan, 1066 CX Amsterdam, The Netherlands
    Nature 415:530-6. 2002
    ..This gene expression profile will outperform all currently used clinical parameters in predicting disease outcome. Our findings provide a strategy to select patients who would benefit from adjuvant therapy...
  4. ncbi DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy
    Ken A Olaussen
    Laboratory of Radiobiology and Oncology, Commissariat a l Energie Atomique, Fontenay aux Roses, University of Paris 11, Paris, France
    N Engl J Med 355:983-91. 2006
    ..Adjuvant cisplatin-based chemotherapy improves survival among patients with completely resected non-small-cell lung cancer, but there is no validated clinical or biologic predictor of the benefit of chemotherapy...
  5. ncbi Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Edward H Romond
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    N Engl J Med 353:1673-84. 2005
    We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer.
  6. ncbi Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18
    B Fisher
    Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Shadyside Hospital, PA, USA
    J Clin Oncol 15:2483-93. 1997
    ..To determine whether preoperative doxorubicin and cyclophosphamide (AC) permits more lumpectomies to be performed and decreases the incidence of positive nodes in women with primary breast cancer...
  7. ncbi Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer
    Timothy Winton
    National Cancer Institute of Canada Clinical Trials Group, Kingston, Ont
    N Engl J Med 352:2589-97. 2005
    ..We undertook to determine whether adjuvant vinorelbine plus cisplatin prolongs overall survival among patients with completely resected early-stage non-small-cell lung cancer...
  8. ncbi Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis
    Val Gebski
    National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia
    Lancet Oncol 8:226-34. 2007
    ..We aimed to clarify the benefits of neoadjuvant chemoradiotherapy or chemotherapy versus surgery alone by a meta-analysis of randomised trial data...
  9. doi Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial
    Thierry Andre
    Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, Paris 75012, France
    J Clin Oncol 27:3109-16. 2009
    ..7% at 48 months. CONCLUSION Adding oxaliplatin to LV5FU2 significantly improved 5-year DFS and 6-year OS in the adjuvant treatment of stage II or III colon cancer and should be considered after surgery for patients with stage III disease...
  10. ncbi Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial
    Joseph Ragaz
    McGill University Health Center, Royal Victoria Hospital, 687 Pine Ave, Montreal, PQ, Canada H3A 1A1
    J Natl Cancer Inst 97:116-26. 2005
    ..premenopausal patients with lymph node-positive breast cancer treated by modified radical mastectomy and adjuvant chemotherapy. Three hundred eighteen patients were assigned to receive no further therapy or radiation therapy (37...
  11. ncbi Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer
    Mitch Dowsett
    Academic Department of Biochemistry, 4th Floor, Wallace Wing, The Royal Marsden Hospital, Fulham Road, London SW3 6 JJ, UK
    J Natl Cancer Inst 99:167-70. 2007
    ....
  12. ncbi Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety
    Joseph Wee
    Department of Radiation Oncology, National Cancer Center, Singapore 169610, Republic of Singapore
    J Clin Oncol 23:6730-8. 2005
    ..However, there were controversies regarding the applicability of the results to patients in endemic regions. This study aims to confirm the findings of the 00-99 Trial and its applicability to patients with endemic NPC...
  13. ncbi Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
    Ann H Partridge
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, D1210, Boston, MA 02215, USA
    J Clin Oncol 21:602-6. 2003
    ..We sought to estimate adherence and predictors of nonadherence in women starting tamoxifen as adjuvant breast cancer therapy...
  14. ncbi Capecitabine as adjuvant treatment for stage III colon cancer
    Chris Twelves
    University of Leeds and Bradford NHS Hospitals Trust, Leeds, United Kingdom
    N Engl J Med 352:2696-704. 2005
    ..The oral fluoropyrimidine capecitabine is an established alternative to bolus fluorouracil plus leucovorin as first-line treatment for metastatic colorectal cancer. We evaluated capecitabine in the adjuvant setting...
  15. pmc Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer
    Chang Qi Zhu
    University Health Network, Ontario Cancer Institute and Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 28:4417-24. 2010
    ..10 trial demonstrated benefit from adjuvant cisplatin/vinorelbine (ACT) in early-stage non-small-cell lung cancer (NSCLC). We hypothesized that expression profiling may identify stage-independent subgroups who might benefit from ACT...
  16. ncbi Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    Martine J Piccart-Gebhart
    Medicine Department, Jules Bordet Institute, Blvd de Waterloo 125, 1000 Brussels, Belgium
    N Engl J Med 353:1659-72. 2005
    ..We investigated its efficacy and safety after excision of early-stage breast cancer and completion of chemotherapy...
  17. ncbi Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
    Vered Stearns
    The Breast Cancer Program, Department of Medicine, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    J Natl Cancer Inst 95:1758-64. 2003
    ..In a prospective clinical trial, we tested the effects of coadministration of tamoxifen and the SSRI paroxetine, an inhibitor of CYP2D6, on tamoxifen metabolism...
  18. ncbi Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer
    K Bujko
    Department of Radiotherapy, Maria Sklodowska Curie Memorial Cancer Centre, Warsaw, Poland
    Br J Surg 93:1215-23. 2006
    ..The aim of this study was to compare survival, local control and late toxicity in the two treatment groups...
  19. ncbi Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma
    Roger J Packer
    Division of Neurology, Children s National Medical Center, Washington, DC 20010, USA
    J Clin Oncol 24:4202-8. 2006
    ..To determine the event-free survival (EFS) and overall survival of children with average-risk medulloblastoma and treated with reduced-dose craniospinal radiotherapy (CSRT) and one of two postradiotherapy chemotherapies...
  20. doi Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial
    John P Neoptolemos
    Liverpool Cancer Research UK Cancer Trials Unit, Cancer Research UK Centre, University of Liverpool, Fifth Floor, UCD Bldg, Daulby Street, Liverpool, L69 3GA, United Kingdom
    JAMA 304:1073-81. 2010
    ..Gemcitabine is known to be the most effective agent in advanced disease as well as an effective agent in patients with resected pancreatic cancer...
  21. ncbi Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07
    J Philip Kuebler
    National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Pittsburgh, PA, USA
    J Clin Oncol 25:2198-204. 2007
    ..This phase III clinical trial evaluated the impact on disease-free survival (DFS) of adding oxaliplatin to bolus weekly fluorouracil (FU) combined with leucovorin as surgical adjuvant therapy for stage II and III colon cancer...
  22. ncbi Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline
    Katherine M W Pisters
    M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 25:5506-18. 2007
    To determine the role of adjuvant chemotherapy and radiation therapy in patients with completely resected stage IA-IIIA non-small-cell lung cancer (NSCLC).
  23. ncbi Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial
    M Overgaard
    Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
    Lancet 353:1641-8. 1999
    ..In a randomised trial among postmenopausal women who had undergone mastectomy, we compared adjuvant tamoxifen alone with tamoxifen plus postoperative radiotherapy...
  24. pmc Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study
    Priya P Gor
    Center for Cancer and Hematologic Disease, 1930 E Route 70, Cherry Hill, NJ 08003, USA
    Breast Cancer Res 12:R26. 2010
    Cyclophosphamide-based adjuvant chemotherapy is a mainstay of treatment for women with node-positive breast cancer, but is not universally effective in preventing recurrence...
  25. ncbi Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1
    Atsushi Nashimoto
    Department of Surgery, Niigata Cancer Center Hospital, 2 15 3 Kawagishicho, Niigata 951 8566, Japan
    J Clin Oncol 21:2282-7. 2003
    To evaluate the survival benefit of adjuvant chemotherapy after curative resection in serosa-negative gastric cancer patients (excluding patients who were T1N0), we conducted a multicenter phase III clinical trial in which 13 cancer ..
  26. doi Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse
    Katharina Pachmann
    Department of Experimental Hematology and Oncology, Clinic for Internal Medicine II, Friedrich Schiller Universitat Jena, Erlanger Allee 101, D 07747, Jena, Germany
    J Clin Oncol 26:1208-15. 2008
    ..To demonstrate that it is possible to monitor the response to adjuvant therapy by repeated analysis of circulating epithelial tumor cells (CETCs) and to detect patients early who are at risk of relapse...
  27. doi Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials
    Michele De Laurentiis
    Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Napoli, Italy
    J Clin Oncol 26:44-53. 2008
    ..We aimed to determine whether this approach improves disease-free survival (DFS) and overall survival (OS) and whether benefits are maintained across relevant patient subgroups...
  28. ncbi Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial
    Henri Roche
    Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France
    J Clin Oncol 24:5664-71. 2006
    ....
  29. ncbi Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy
    Masatoshi Inagaki
    Psycho Oncology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Chiba, Japan
    Cancer 109:146-56. 2007
    Previous studies have shown cognitive impairment in breast cancer survivors who were exposed to adjuvant chemotherapy. Neural damage by chemotherapy might have played some part in these findings...
  30. ncbi A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung
    Harubumi Kato
    Department of Surgery, Tokyo Medical University, Tokyo, Japan
    N Engl J Med 350:1713-21. 2004
    In a previous phase 3 trial of adjuvant chemotherapy after resection of non-small-cell lung cancer, a combination of uracil and tegafur (often referred to as UFT) taken orally was shown to prolong survival...
  31. ncbi International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer
    Nicoletta Colombo
    European Institute of Oncology, Milan, Italy
    J Natl Cancer Inst 95:125-32. 2003
    The question of whether platinum-based adjuvant chemotherapy can improve outcomes in patients with early-stage epithelial ovarian cancer is an important one...
  32. ncbi Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer
    J P Pignon
    Department of Biostatistics and Epidemiology, Institut Gustav Roussy, Villejuif, France
    Lancet 355:949-55. 2000
    ..We did three meta-analyses of the impact of survival on chemotherapy added to locoregional treatment...
  33. ncbi HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials
    Alessandra Gennari
    National Cancer Research Institute, Largo Rosanna Benzi, 10 16132 Genoa, Italy
    J Natl Cancer Inst 100:14-20. 2008
    b>Adjuvant chemotherapy with anthracyclines improves disease-free and overall survival compared with non-anthracycline-based adjuvant chemotherapy regimens in the treatment of early breast cancer...
  34. ncbi A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer
    John P Neoptolemos
    Department of Surgery, Liverpool University, Liverpool, United Kingdom
    N Engl J Med 350:1200-10. 2004
    ..The effect of adjuvant treatment on survival in pancreatic cancer is unclear. We report the final results of the European Study Group for Pancreatic Cancer 1 Trial and update the interim results...
  35. ncbi The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature
    Marina G Falleti
    School of Psychological Science, LaTrobe University, Level 7, 21 Victoria Street, Melbourne, VIC 3053, Australia
    Brain Cogn 59:60-70. 2005
    Several studies have identified that adjuvant chemotherapy for breast cancer is associated with cognitive impairment; however, the magnitude of this impairment is unclear...
  36. ncbi Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group
    A Recht
    Joint Center for Radiation Therapy, Harvard Medical School, and Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Clin Oncol 17:1689-700. 1999
    ....
  37. ncbi Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study
    Dora L W Kwong
    Department of Clinical Oncology, University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong
    J Clin Oncol 22:2643-53. 2004
    To study the efficacy of concurrent chemoradiotherapy (CRT) and adjuvant chemotherapy (AC) for nasopharyngeal carcinoma (NPC).
  38. ncbi The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer
    Masahiro Tsuboi
    Department of Thoracic Surgery and Oncology, Tokyo Medical University and Hospital, Tokyo, Japan
    Ann Thorac Cardiovasc Surg 13:73-7. 2007
    ..Although adjuvant chemotherapy is the standard practice for patients with stages I-III breast and colorectal cancer, the therapeutic ..
  39. ncbi Adjuvant docetaxel for node-positive breast cancer
    Miguel Martin
    Hospital Universitario San Carlos, Madrid, Spain
    N Engl J Med 352:2302-13. 2005
    We compared docetaxel plus doxorubicin and cyclophosphamide (TAC) with fluorouracil plus doxorubicin and cyclophosphamide (FAC) as adjuvant chemotherapy for operable node-positive breast cancer.
  40. ncbi Primary bone osteosarcoma in the pediatric age: state of the art
    Alessandra Longhi
    Chemotherapy Surgery of the Musculoskeletal, Oncology Department at Rizzoli Orthopaedic Institute, Bologna, Italy
    Cancer Treat Rev 32:423-36. 2006
    ..effective drugs are still the same as those employed over the last 20 years as front line neoadjuvant or adjuvant chemotherapy: Doxorubicin, Cisplatin, Methotrexate, Ifosfamide...
  41. doi Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma
    Anne W M Lee
    Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong, China
    J Natl Cancer Inst 102:1188-98. 2010
    Current practice of adding concurrent-adjuvant chemotherapy to radiotherapy (CRT) for treating advanced nasopharyngeal carcinoma is based on the Intergroup-0099 Study published in 1998...
  42. ncbi Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer
    Takashi Tsuji
    Division of Surgical Oncology, Department of Translational Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852 8501, Japan
    Clin Cancer Res 9:3700-4. 2003
    ..not the TSER genotype is an efficacious marker for tumor sensitivity to 5-fluorouracil (5-FU)-based oral adjuvant chemotherapy for colorectal cancer...
  43. ncbi Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial
    H H Hartgrink
    Department of Surgery, Leiden University Medical Centre, P O Box 9600, 2300 RC Leiden, The Netherlands
    Eur J Surg Oncol 30:643-9. 2004
    ..We performed a randomised trial with pre-operative FAMTX vs. surgery alone in order to evaluate the effect of pre-operative chemotherapy on resectability and survival...
  44. pmc Completion of therapy by Medicare patients with stage III colon cancer
    Sharon A Dobie
    Department of Family Medicine, University of Washington, Seattle, WA 98195 6390, USA
    J Natl Cancer Inst 98:610-9. 2006
    Certain factors, such as race or age, are known to be associated with variation in initiation of adjuvant chemotherapy for stage III colon cancer, but little is known about what factors are associated with completion of adjuvant therapy...
  45. doi Adjuvant chemotherapy for early colon cancer: what survival benefits make it worthwhile?
    Prunella Blinman
    NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia
    Eur J Cancer 46:1800-7. 2010
    We sought to determine the minimum survival benefits that patients judged sufficient to make adjuvant chemotherapy for early colon cancer worthwhile, factors associated with these judgments; and, to compare a self-administered ..
  46. ncbi Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer
    Roman Rouzier
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 23:8331-9. 2005
    ..To combine clinical variables associated with pathologic complete response (pCR) and distant metastasis-free survival (DMFS) after preoperative chemotherapy (PC) into a prediction nomogram...
  47. pmc The effect of comorbidity on the use of adjuvant chemotherapy and survival from colon cancer: a retrospective cohort study
    Diana Sarfati
    Department of Public Health, University of Otago Wellington, PO Box 7343, Wellington 6242, New Zealand
    BMC Cancer 9:116. 2009
    ..This study aimed to assess the impact of comorbidity on colon cancer patient survival, the effect of comorbidity on treatment choices for these patients, and the impact of this on survival among those with comorbidity...
  48. ncbi Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival
    P I Haigh
    Department of Surgical Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    Cancer 91:2335-42. 2001
    ..The prognosis of anaplastic thyroid carcinoma (ATC) has been dismal. The objective of this study was to identify prognostic factors in patients who had prolonged survival...
  49. doi Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial
    M Mandala
    Department of Oncology and Hematology, Ospedali Riuniti di Bergamo, Largo Barozzi 1, Bergamo, Italy
    Ann Oncol 21:871-6. 2010
    Acquired and inherited risk factors for venous thromboembolism (VTE) and the incidence of symptomatic VTE were investigated in patients on adjuvant chemotherapy for breast or gastrointestinal cancer (GI).
  50. ncbi Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli
    G Bacci
    Departments of Musculo Skeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Clin Oncol 18:4-11. 2000
    ..The identification of prognostic factors in patients with nonmetastatic Ewing's sarcoma could allow the use of risk-adapted therapeutic strategies of treatment...
  51. doi Adjuvant chemotherapy after resection in elderly Medicare and Medicaid patients with colon cancer
    Cathy J Bradley
    Department of Health Administration and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298 0203, USA
    Arch Intern Med 168:521-9. 2008
    This study investigated the influence of Medicaid enrollment on the receipt and completion of adjuvant chemotherapy and the likelihood of evaluation by an oncologist for those patients who do not initiate chemotherapy.
  52. ncbi Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial
    J Baptist Trimbos
    Leiden University Medical Center, Leiden, The Netherlands
    J Natl Cancer Inst 95:113-25. 2003
    All randomized trials of adjuvant chemotherapy for early-stage ovarian cancer have lacked the statistical power to show a difference in the effect on survival between adjuvant chemotherapy and no adjuvant chemotherapy...
  53. doi Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases
    Dan G Blazer
    Department of Surgical Oncology, Gastrointestinal Medical Oncology, and Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 26:5344-51. 2008
    ..The secondary goal of the study was to identify the clinical predictors of pathologic response...
  54. doi Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer
    Nikolaos Xenidis
    Department of Medical Oncology, University General Hospital, Heraklion, Crete, Greece
    J Clin Oncol 27:2177-84. 2009
    To evaluate the prognostic significance of cytokeratin-19 (CK-19) mRNA-positive circulating tumor cells (CTCs) in peripheral blood of women with early-stage breast cancer after the completion of adjuvant chemotherapy.
  55. pmc Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer
    Tomasz P Srokowski
    Division of Cancer Medicine, and Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 27:2170-6. 2009
    To evaluate whether diabetes affects patterns of adjuvant chemotherapy use, toxic effects of chemotherapy, and breast cancer outcomes.
  56. ncbi Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials
    T Ono
    Second Department of Surgery, Shimane Medical University, Izumo, Japan
    Cancer 91:2378-85. 2001
    The goal of the current study was use metaanalysis to evaluate the effect of postoperative adjuvant chemotherapy after resection of hepatocellular carcinoma (HCC), especially in cirrhotic patients.
  57. ncbi An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach
    Sung Kim
    Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Kangnam Gu, Seoul, South Korea
    Int J Radiat Oncol Biol Phys 63:1279-85. 2005
    ..We investigated the effect of postoperative chemoradiotherapy on the relapse rate and survival rate of patients with D2-resected gastric cancer...
  58. ncbi Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial
    Herve Bonnefoi
    Geneva University Hospital, Geneva, Switzerland
    Lancet Oncol 8:1071-8. 2007
    ..The aim of this study was to confirm the validity of these gene-expression signatures in a large series of patients with oestrogen-receptor-negative breast tumours who were treated in a phase III neoadjuvant clinical trial...
  59. pmc MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma
    Johannes Voortman
    Medical Oncology Branch and Laboratory of Human Carcinogenesis, National Cancer Institute, NIH, Bethesda, Maryland 20892 1906, USA
    Cancer Res 70:8288-98. 2010
    ..in the International Adjuvant Lung Cancer Trial (IALT), the largest randomized study conducted to date of adjuvant chemotherapy in patients with radically resected non-small cell lung carcinoma (NSCLC)...
  60. doi Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
    Priya Rastogi
    University of Pittsburgh Cancer Institute Magee Womens Hospital, 300 Halket St, Room 3524, Pittsburgh, PA 15213, USA
    J Clin Oncol 26:778-85. 2008
    ..Protocol B-27 was designed to determine the effect of adding docetaxel (T) to preoperative AC on tumor response rates, DFS, and OS...
  61. doi Treatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy-the national cancer centre singapore experience
    Ivan Weng Keong Tham
    Department of Radiation Oncology, National Cancer Centre, Singapore
    Int J Radiat Oncol Biol Phys 75:1481-6. 2009
    ..The aim of this study was to determine the efficacy and acute toxicity of our early experience with treating nasopharyngeal carcinoma (NPC) patients with intensity-modulated radiotherapy (IMRT)...
  62. ncbi Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols
    Stefan S Bielack
    Klinik und Poliklinik für Kinderheilkunde, Pädiatrische Hämatologie Onkologie, Universitatsklinikum, Munster, Germany
    J Clin Oncol 20:776-90. 2002
    ..To define prognostic factors for response and long-term outcome for a wide spectrum of osteosarcomas, extending well beyond those of the typical young patient with seemingly localized extremity disease...
  63. ncbi Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate
    C A Lawton
    Medical College of Wisconsin, Radiation Oncology, Milwaukee, WI 53226, USA
    Int J Radiat Oncol Biol Phys 49:937-46. 2001
    ..To determine the potential advantage of androgen ablation following standard external-beam radiation therapy in patients with locally advanced (clinical or pathologic T3; clinical or pathologic node positive) carcinoma of the prostate...
  64. ncbi Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy
    W Demark-Wahnefried
    Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 19:2381-9. 2001
    Weight gain is a common problem among breast cancer patients who receive adjuvant chemotherapy (CT). We undertook a study to determine the causes of this energy imbalance.
  65. ncbi Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study
    M D Ris
    Division of Psychology, Children s Hospital Medical Center, University of Cincinnati, Cincinnati, OH, USA
    J Clin Oncol 19:3470-6. 2001
    To investigate the intellectual outcomes of children with medulloblastomas/primitive neuroectodermal tumors (MB/PNET) treated with reduced-dose craniospinal radiotherapy (RT) plus adjuvant chemotherapy.
  66. doi Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2
    B Chauffert
    Department of Oncology, Anticancer Center G F Leclerc, Dijon, France
    Ann Oncol 19:1592-9. 2008
    ..The role of chemoradiation with systemic chemotherapy compared with chemotherapy alone in locally advanced pancreatic cancer (LAPC) is uncertain...
  67. ncbi Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer
    Deborah Schrag
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:3999-4005. 2002
    Clinical trials have not demonstrated that adjuvant chemotherapy improves survival for patients with resected stage II colon cancer. Nevertheless, patients may receive this treatment despite its uncertain benefit...
  68. ncbi A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
    Paul E Goss
    Division of Hematology Oncology, Princess Margaret Hospital, Toronto, ON, Canada
    N Engl J Med 349:1793-802. 2003
    ..The aromatase inhibitor letrozole, by suppressing estrogen production, might improve the outcome after the discontinuation of tamoxifen therapy...
  69. doi Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer
    Ana Belén Custodio
    Medical Oncology Department, Hospital Universitario Clinico San Carlos, Center affiliate to the Red Temática de Investigación Cooperativa RD06 0020 0021, Instituto de Salud Carlos III ISCIII, Madrid, Spain
    J Thorac Oncol 4:891-910. 2009
    ..Multiple large randomized trials have demonstrated that adjuvant chemotherapy using modern cisplatin-based regimens can significantly improve 5-year survival in carefully selected ..
  70. ncbi International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma
    J Baptist Trimbos
    Department of Gynecology, Leiden University Medical Center, The Netherlands
    J Natl Cancer Inst 95:105-12. 2003
    b>Adjuvant chemotherapy has been suggested as a possible strategy to improve survival in women with early-stage ovarian cancer; however, all randomized studies to date have been too small to answer this question reliably.
  71. ncbi Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery
    L Rubbia-Brandt
    Unit of Gastrointestinal and Liver Pathology, University Hospital, Geneva, Switzerland
    Ann Oncol 18:299-304. 2007
    ....
  72. ncbi MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer
    L Esserman
    Department of Surgery, University of California, San Francisco, USA
    Ann Surg Oncol 8:549-59. 2001
    ..Magnetic resonance imaging (MRI) demonstrates that patients with LABC have distinct tumor patterns. We investigated whether or not these patterns predict response to therapy...
  73. ncbi Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer
    G Gnanasampanthan
    Department of Surgery, University of Western Australia, Nedlands, 6907, Australia
    J Pathol 195:543-8. 2001
    ..types in a retrospective series of 430 Dukes' C stage CRC patients, of whom 208 (48%) had received adjuvant chemotherapy with 5-fluorouracil/levamisole or 5-fluorouracil/leucovorin...
  74. ncbi Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial
    Kerry S Courneya
    Faculty of Physical Education and Recreation, University of Alberta, Edmonton, Alberta, Canada
    J Clin Oncol 25:4396-404. 2007
    ..We evaluated the relative merits of aerobic and resistance exercise in blunting these effects...
  75. ncbi Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma
    David E Stein
    Division of Colorectal Surgery, Department of Surgery, Jefferson Medical College, Philadelphia, PA, USA
    Dis Colon Rectum 46:448-53. 2003
    ..Our purpose was to determine whether a longer time interval between completion of therapy and resection increases tumor downstaging and affects perioperative morbidity...
  76. doi Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials
    M Clarke
    Lancet 371:29-40. 2008
    ....
  77. pmc MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy
    Andreas Claudius Hoffmann
    Department of Medicine Cancer Research, West German Cancer Center, University Duisburg Essen, Essen, Germany
    Neoplasia 12:628-36. 2010
    The role of adjuvant chemotherapy in patients with locally advanced bladder cancer still remains to be defined...
  78. doi Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy
    Shigetsugu Takano
    The Department of General Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
    Ann Surg Oncol 15:3157-68. 2008
    ..The purpose of this study was to determine novel factors that make pancreatic cancer resistant to gemcitabine...
  79. doi The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer
    Michael Knauer
    Division of Diagnostic Oncology, Netherlands Cancer Institute, Plesmanlaan, Amsterdam, The Netherlands
    Breast Cancer Res Treat 120:655-61. 2010
    ..This benefit was not significant in low risk patients, who were at such low risk for recurrence and cancer-related death, that adding CT does not appear to be clinically meaningful...
  80. ncbi Locally advanced pancreatic cancer
    Christopher G Willett
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 23:4538-44. 2005
    ..These treatments include external-beam irradiation with and without fluorouracil-based chemotherapy, intraoperative irradiation, and, more recently, external-beam irradiation with new systemic targeted agents...
  81. doi Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity?
    Nancy L Keating
    Division of General Internal Medicine and the Department of Surgery and Center for Surgery and Public Health, Brigham and Women s Hospital, USA
    J Clin Oncol 26:2532-7. 2008
    We surveyed cancer physicians to understand how patients' age and comorbidity influence adjuvant chemotherapy recommendations and whether physician or practice characteristics also affect these recommendations.
  82. ncbi Optimizing endocrine therapy for breast cancer
    Eric P Winer
    J Clin Oncol 23:1609-10. 2005
  83. ncbi Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial
    Patricia A Ganz
    School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA
    J Natl Cancer Inst 96:376-87. 2004
    ..We investigated the baseline psychosocial status of women enrolled in a randomized trial testing two psychosocial interventions for women at the end of primary treatment...
  84. ncbi Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02
    N Wolmark
    N Wolmark, D L Wickerham, E R Fisher, B Fisher, National Surgical Adjuvant Breast and Bowel Project NSABP Operations Center, Pittsburgh, PA 15212, USA
    J Natl Cancer Inst 92:388-96. 2000
    ..This study was carried out to address this issue. An additional aim was to determine whether leucovorin (LV)-modulated 5-fluorouracil (5-FU) is superior to the combination of 5-FU, semustine, and vincristine (MOF) in men...
  85. ncbi Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    N Engl J Med 354:809-20. 2006
    ..We compared docetaxel with vinorelbine for the adjuvant treatment of early breast cancer. Women with tumors that overexpressed HER2/neu were also assigned to receive concomitant treatment with trastuzumab or no such treatment...
  86. pmc The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy
    P Manders
    Department of Medical Oncology, University Medical Centre Nijmegen, Nijmegen, The Netherlands
    Br J Cancer 87:772-8. 2002
    ..This implies that vascular endothelial growth factor is related with the natural course of breast cancer progression...
  87. ncbi Effect of screening and adjuvant therapy on mortality from breast cancer
    Donald A Berry
    Department of Biostatistics and Applied Mathematics, M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 353:1784-92. 2005
    ..We used modeling techniques to assess the relative and absolute contributions of screening mammography and adjuvant treatment to the reduction in breast-cancer mortality in the United States from 1975 to 2000...
  88. doi Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer
    Enriqueta Felip
    Vall d Hebron University Hospital, Barcelona, Spain
    J Clin Oncol 28:3138-45. 2010
    To address whether preoperative chemotherapy plus surgery or surgery plus adjuvant chemotherapy prolongs disease-free survival compared with surgery alone among patients with resectable non-small-cell lung cancer.
  89. doi Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy
    Paul L Nguyen
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA
    J Clin Oncol 26:2373-8. 2008
    ..To determine whether breast cancer subtype is associated with outcome after breast-conserving therapy (BCT) consisting of lumpectomy and radiation therapy...
  90. doi Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
    Cornelia Liedtke
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 1439, USA
    J Clin Oncol 26:1275-81. 2008
    ..In this study, we compared response to neoadjuvant chemotherapy and survival between patients with TNBC and non-TNBC...
  91. ncbi Cancer of the ovary
    Stephen A Cannistra
    Program of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    N Engl J Med 351:2519-29. 2004
  92. ncbi Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer
    H Elsaleh
    Department of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, Australia
    Lancet 355:1745-50. 2000
    b>Adjuvant chemotherapy can improve 5-year survival in Dukes' C colorectal carcinoma. Improved selection of patients who will respond to adjuvant treatments is required...
  93. ncbi Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group
    A Bamias
    Department of Clinical TherapeuticsUniversity of Athens, School of Medicine, Athens, Greece
    J Clin Oncol 22:2150-4. 2004
    ..We prospectively studied a cohort of patients who underwent surgery for high-risk carcinoma of the upper urinary tract to assess the feasibility of the combination of paclitaxel and carboplatin as adjuvant treatment...
  94. pmc Adjuvant chemotherapy in older women with early-stage breast cancer
    Hyman B Muss
    University of Vermont, Burlington, USA
    N Engl J Med 360:2055-65. 2009
    Older women with breast cancer are underrepresented in clinical trials, and data on the effects of adjuvant chemotherapy in such patients are scant...
  95. ncbi Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer
    Nadine Tchen
    Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 21:4175-83. 2003
    There is evidence that cognitive dysfunction, fatigue, and menopausal symptoms may occur in women receiving adjuvant chemotherapy for breast cancer...
  96. pmc Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies
    Thomas Hogberg
    Department of Cancer Epidemiology, University of Lund, University Hospital, Lund, Sweden
    Eur J Cancer 46:2422-31. 2010
    ..The two studies were pooled...
  97. pmc Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data
    R Arriagada
    Meta analysis Group, MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK
    Lancet 375:1267-77. 2010
    Many randomised controlled trials have investigated the effect of adjuvant chemotherapy in operable non-small-cell lung cancer...
  98. ncbi Predictive value of Aurora-A/STK15 expression for late stage epithelial ovarian cancer patients treated by adjuvant chemotherapy
    Silke Lassmann
    Institute of Pathology, University Hospital, Albert Ludwigs University Freiburg, Freiburg, Germany
    Clin Cancer Res 13:4083-91. 2007
    ....
  99. ncbi Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices
    Gary H Lyman
    James P Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, NY 14642, USA
    J Clin Oncol 21:4524-31. 2003
    This retrospective study was undertaken to assess practice patterns in adjuvant chemotherapy for early-stage breast cancer (ESBC) and to define the incidence and predictive factors of reduced relative dose-intensity (RDI).
  100. ncbi 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
    Ian Smith
    Royal Marsden Hospital, London, UK
    Lancet 369:29-36. 2007
    ..We investigated the drug's effect on overall survival after a median follow-up of 2 years in the Herceptin Adjuvant (HERA) study...
  101. ncbi Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors
    Sylvain L'espérance
    Department of Medicine, Faculty of Medicine, Laval University, Quebec G1K 7P4, Canada
    Int J Oncol 29:5-24. 2006
    ..This type of molecular profiling could have important clinical implications in resolving chemoresistance and the development of novel treatment strategies designed to prevent its emergence...

Research Grants65

  1. Role of Stat3 in Breast Cancer Tumorigenesis
    Jacqueline F Bromberg; Fiscal Year: 2010
    ..Micrometastasis in the blood and bone marrow are the principal targets for adjuvant chemotherapy and hormonal therapy...
  2. In vivo imaging of encapsulated stem cells in mouse models of tumor resection
    Khalid A Shah; Fiscal Year: 2013
    ..glioblastoma multiforme (GBM) includes maximal surgical tumor resection followed by radiation therapy and adjuvant chemotherapy. However, recurrence rates of GBM and the associated patient mortality are nearly 100%...
  3. Technology to improve the assessment of tissue-associated protein biomarkers
    JEFFREY THOMAS MASON; Fiscal Year: 2013
    ..standard for clinical discrimination between good and poor prognosis and for deciding if patients receive adjuvant chemotherapy following surgery...
  4. NORTH CENTRAL CANCER TREATMENT GROUP
    Jan C Buckner; Fiscal Year: 2013
    ..oxaliplatin-based treatment regimens in advanced colorectal cancer and the combination of trastuzumab with adjuvant chemotherapy for patients with loco-regional breast cancer overexpressing the HER-2 protein...
  5. Prognostic and predictive gene sets in HER2-positive breast cancer:The HERA Trial
    Brian Leyland Jones; Fiscal Year: 2010
    ..2 years of trastuzumab versus no trastuzumab in women with HER2+ primary breast cancer that have completed adjuvant chemotherapy, demonstrated a significant improvement in disease-free survival among women with HER2-positive breast ..
  6. A Novel Computational Framework for Individualized Clinical Decision-Making
    Nancy Lan Guo; Fiscal Year: 2013
    ..be developed to predict the risk for tumor recurrence in early-stage patients and to select patients for adjuvant chemotherapy. Lung cancer is difficult to manage clinically, and tumor recurrence is the major cause of treatment ..
  7. Cranial Stimulation for Chemotherapy Symptoms in Breast Cancer
    Deborah B McGuire; Fiscal Year: 2013
    ..fatigue, pain and sleep disturbances) in women (N=150) with early-stage breast cancer (BC) over the adjuvant chemotherapy treatment period...
  8. Cognitive Behavioral Effects on Sleep, Pain, and Cytokines in Gynecologic Cancer
    Deidre B Pereira; Fiscal Year: 2013
    ..effects on patient- centered and physiological outcomes among women with gynecologic cancers undergoing adjuvant chemotherapy. Grounded within the Central Arousal Theory of Stress (CATS) and a biobehavioral model of tumor biology, ..
  9. MicroRNA profiling to predict recurrence after resection of early lung cancer
    Saikrishna Yendamuri; Fiscal Year: 2013
    ..Such prognostication will enable the identification of cases for adjuvant chemotherapy to improve the chances of cure while minimizing the risk...
  10. Pharmacogenetics of Tamoxifen and Chemotherapies and Risk of Contralateral Breast
    Jane C Figueiredo; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Adjuvant chemotherapy and tamoxifen have been shown to reduce the risk of contralateral breast cancer (CBC) among women with a previous history of breast cancer...
  11. Predictors of therapeutic response in the treatment of esophageal adenocarcinoma
    ANDREW CHING HUNG CHANG; Fiscal Year: 2012
    ..Relevance: Identification and validation of potential biomarkers for response to chemotherapy ultimately can provide the clinician with additional means of providing specific, directed therapy for the individual patient. ..
  12. Screening of inhibitors for human 5-prime-tyrosyl DNA phosphodiesterase (hTDP2)
    Sanjay Adhikari; Fiscal Year: 2013
    ..sensitivity to the TopII- targeting agent etoposide, demonstrating that hTDP2 can be a target for adjuvant chemotherapy. Our hypothesis is effective inhibition of hTDP2 will increase the cancer cell killing efficacy of TopII ..
  13. Molecular Characterization of Stage I Lung Cancer
    Ming You; Fiscal Year: 2010
    ..b>Adjuvant chemotherapy in an unselected group of patients with resected stage l-lll produces only modest improvement in survival...
  14. Dietary and Lifestyle Determinants of Colon Cancer Recurrence and Survival
    Charles S Fuchs; Fiscal Year: 2011
    ..Nonetheless, 40-45% of stage III patients receiving current adjuvant chemotherapy will develop metastases...
  15. Identification of microRNAs as blood-based markers for colorectal cancer
    Wei Zhang; Fiscal Year: 2012
    ..A successful blood test would be a major help in deciding on neoadjuvant or adjuvant chemotherapy, and would also be used to follow patients for recurrence after curative resection and after chemotherapy ..
  16. Impact of Celecoxib and Inflammation on Survival in Stage III Colon Cancer
    Charles S Fuchs; Fiscal Year: 2013
    ..who receive adjuvant fluorouracil-based chemotherapy, 35-40% of stage III patients receiving current adjuvant chemotherapy still develop cancer recurrence...
  17. Neuropsychological Predictors of Functional Decline in Elders with Cancer
    JASON ELLSWORTH SCHILLERSTROM; Fiscal Year: 2011
    ..status and neuropsychological performance observed in non-demented elders with colon cancer referred for adjuvant chemotherapy compared to a cancer-free elder control group...
  18. Work Outcomes of Colon and Rectal Cancer Survivors
    Carolyn Y Fang; Fiscal Year: 2012
    ..diagnosed in the same calendar year and have completed primary treatment (surgery, neo-adjuvant and/or adjuvant chemotherapy, and/or radiotherapy) by the time of the survey;2) were employed in a paid job at the time of cancer ..
  19. Predictors of ovarian failure after chemotherapy in young breast cancer patients
    HUI CHUN IRENE SU; Fiscal Year: 2013
    ..significant hormonal, genetic and ovarian morphometric markers associated with ovarian failure after adjuvant chemotherapy. A 5-year prospective cohort study of pre- menopausal breast cancer patients, followed from diagnosis to ..
  20. Racial/Ethnic and SES Disparities in Quality of Breast Cancer Systemic Therapy
    Steven J Katz; Fiscal Year: 2013
    ..The underlying reasons for observed patterns and correlates of quality adjuvant chemotherapy and hormonal therapy are unknown...
  21. Pharmacogenomics of Breast Cancer Adjuvant Chemotherapy
    Richard M Weinshilboum; Fiscal Year: 2011
    ..We propose that we perform a GWA study using DNA samples from the Success A breast cancer trial of adjuvant chemotherapy. Breast cancer, the most common cancer, and the second-leading cause of cancer death in women, is of major ..
  22. Do Medicare Claims Measure Cancer Relapse Patients: An External Validation Study
    Elizabeth B Lamont; Fiscal Year: 2012
    ..survival (DFS) of elderly colorectal (CRC) and breast cancer patients following receipt standard adjuvant chemotherapy. DFS is one of the MOST important end-points in adjuvant chemotherapy in trials, representing the time to ..
  23. Validating Molecular Signature Risk Models of NSCLC
    David H Harpole; Fiscal Year: 2010
    ..phase III trials have demonstrated a survival advantage for stage IB to IMA patients treated with adjuvant chemotherapy [cisplatin/vinorelbine (NCI-C JBR-10);carboplatin/paclitaxel (CALGB 9633)]...
  24. A Novel Computational Framework for Individualized Clinical Decision-Making
    Nancy Lan Guo; Fiscal Year: 2010
    ..This strategy will allow patient stratification based on risk of tumor recurrence and the need for adjuvant chemotherapy. The biomarker interactions derived in Dempster-Shafer networks and Bayesian networks will be evaluated ..
  25. Nanoparticle-mediated support of cancer immunotherapy
    Darrell J Irvine; Fiscal Year: 2013
    ....
  26. DASL-CRC: A Novel Approach to Identify Molecular Markers of Metastatic Recurrence
    STEVEN MONROE LIPKIN; Fiscal Year: 2009
    ..The majority of patients with stage II disease in Europe and the Americas therefore do not receive adjuvant chemotherapy after surgery...
  27. Biodegradable Drug-Eluting Surgical Meshes with Tunable Release Kinetics
    JOHN JOHN SCHWARTZ; Fiscal Year: 2013
    ..The utilization of adjuvant chemotherapy is limited by high systemic toxicities and poor localization to the site of disease...
  28. Multimodal MRI Biomarker of Mild Cognitive Impairment in Breast Cancer
    JEFFREY SCOTT WEFEL; Fiscal Year: 2013
    ..provided by applicant): Women with breast cancer, particularly those who are older and who receive adjuvant chemotherapy, are at significantly increased risk for mild cognitive impairment (MCI)...
  29. Advanced MRI methods for detecting pseudo-progression of glioblastomas
    Harish Poptani; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Neo-adjuvant chemotherapy with temozolomide, along with radiation therapy has become the standard of care for the treatment of gliomas as this regimen improves survival of newly diagnosed ..
  30. B7-H3 in prognosis and immunotherapy of pancreatic cancer
    Xinhui Wang; Fiscal Year: 2010
    ..Even with a complete surgical resection and adjuvant chemotherapy the actual 5 year survival is only 12%...
  31. EASTERN COOPERATIVE ONCOLOGY GROUP
    Joseph Sparano; Fiscal Year: 2013
    ..the standard of care for operable breast cancer (E1199 - NEJM, 2008) and influenced choice of the standard adjuvant chemotherapy for the ongoing adjuvant E5103 breast cancer trial...
  32. Single-cell phenotyping for therapeutic stratification in pancreatic cancer
    Denis Wirtz; Fiscal Year: 2013
    ..We will determine phenotypic patterns predicting the response to adjuvant chemotherapy and subsequent pattern of metastatic failure, to identify tissue-based phenotypic patterns of an ..
  33. Integrative prediction models for metastasis risk in colon cancer
    Xi Chen; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): While adjuvant chemotherapy for stage III colon cancer results in an overall survival benefit, 42 to 44% of stage III patients will not recur in five years even without adjuvant treatment...
  34. Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults
    Arti Hurria; Fiscal Year: 2013
    ..Interface), is to develop a "bedside to bench" model of clinical and biological predictors for toxicity to adjuvant chemotherapy in older adults with breast cancer...
  35. Decision Support System for Predicting outcome of ER+ breast cancers
    Anant Madabhushi; Fiscal Year: 2011
    ..identifying the subset of women with ER+ breast cancer for whom hormonal therapy alone is sufficient, and adjuvant chemotherapy is not required...
  36. Proinflammatory T Regulatory Cells in Colon Cancer
    Khashayarsha Khazaie; Fiscal Year: 2013
    ..phenotype and recovery of normal Treg functions after surgical removal of the tumor and during adjuvant chemotherapy. In parallel we will follow tumor specific T-cell response and seek to evaluate the combined information ..
  37. Cognitive Function and Breast Cancer: Genomics and Disease Characteristics
    THERESA ANN KOLECK; Fiscal Year: 2013
    ..will be used to explore cognitive function prior to and over time following the initiation of adjuvant chemotherapy and/or hormonal therapy...
  38. Structural and functional brain magnetic resonance imaging findings of chemothera
    BIHONG CHEN; Fiscal Year: 2013
    ..b>Adjuvant chemotherapy has been proven to decrease the risks of relapse and mortality from breast cancer...
  39. Ultrastaging of Early Colon Cancer
    Anton J Bilchik; Fiscal Year: 2012
    ..Because patients will not receive adjuvant chemotherapy, we will be able to determine whether nodal MM identified by IHC and/or qRT have an impact on disease-free ..
  40. Predicting Adjuvant Chemotherapy Response in Lung Cancer
    Yang Xie; Fiscal Year: 2013
    ..b>Adjuvant chemotherapy is increasingly used as the standard of care for patients with resected Non-Small-Cell Lung Cancer (NSCLC)...
  41. Development of a plectin-1 targeted payload delivery system for treating pancreat
    Stephanie Thomas; Fiscal Year: 2012
    ..Indeed, the 5 year survival rate is below 5%. Radical resection with adjuvant chemotherapy is potentially curative, but less than 15% of patients qualify for resection (local disease)...
  42. A Novel Breast Cancer Biomarker
    Dennis C Sgroi; Fiscal Year: 2013
    ..breast cancer patients who will benefit from hormonal therapy alone and those who will benefit from the addition of adjuvant chemotherapy, and may provide for novel therapeutic strategies for women with tamoxifen-resistant disease.
  43. Chemotherapy effect on brain structure, neurophysiology and psychomotor behavior
    Guang H Yue; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Adjuvant chemotherapy (CTh) is an established postoperative treatment often prescribed to cancer patients to reduce risk of relapse...
  44. Managed Care Penetration and Cancer Care
    Nancy Keating; Fiscal Year: 2003
    ..of care (annual mammography following initial therapy for women diagnosed with early-stage breast cancer; adjuvant chemotherapy for patients diagnosed with stage III colon cancer; adjuvant chemotherapy and radiation therapy for ..
  45. MCAV in Organ-Confined Bladder CA based on p53 Status
    Richard Cote; Fiscal Year: 2006
    ..We have shown that (1) adjuvant chemotherapy prolongs the recurrence free interval in a group of patients with invasive TCC at high risk for recurrence ..
  46. Association of breast cancer and its therapies with fracture
    Joan Neuner; Fiscal Year: 2009
    ..Second, clinical trials in premenopausal women have shown rapid losses in bone density after cytotoxic adjuvant chemotherapy. Evidence is more limited among postmenopausal women, but animal studies and single-center human studies ..
  47. Stem Cells as Delivery Vehicles and Imaging Probes for Glioma Gene Therapy
    Syed Ali; Fiscal Year: 2009
    ..Surgery and radiation therapy (followed by adjuvant chemotherapy), which form the standard practice, very often fail because of uncertainty in delineating the margin of ..
  48. STRENGTH--Survivor TRaining for ENhancinG Total Health
    Wendy Demark Wahnefried; Fiscal Year: 2002
    Weight gain is a common side effect that accompanies adjuvant chemotherapy for breast cancer...
  49. GUANYLYL CYCLASE C AS A BI0MARKER FOR COLORECTAL CANCER
    Scott Waldman; Fiscal Year: 2006
    ..staging is crucial because it determines prognosis and influences management including administration of adjuvant chemotherapy. Guanylyl cyclase C (GCC) is specifically expressed only by normal intestinal mucosal and colorectal ..
  50. Apolipoprotein E Genotype and Cognitive Performance in Breast Cancer Survivors
    Brent Small; Fiscal Year: 2007
    ..that women diagnosed with early stage breast cancer may experience cognitive problems as a consequence of adjuvant chemotherapy. In addition, research suggests that the presence of the e4 allele of APOE may also convey a disadvantage ..
  51. Liver Regeneration in Man--Effects or Adjuvant Therapy
    Yuman Fong; Fiscal Year: 2005
    ..In experimental models, the liver regenerative process stimulates growth of residual tumor. Adjuvant chemotherapy or oncolytic viral therapy strives to eradicate microscopic residual tumor...
  52. COMBINED RADIOIMMUNOTHERAPY & CHEMOTHERAPY--COLON CANCER
    Malik Juweid; Fiscal Year: 1999
    b>Adjuvant chemotherapy with 5-fluorouracil (5-FU) and leucovorin (LV) has proven to be beneficial in the management of patients with Dukes' B and C colon cancer (1)...
  53. TUMOR MARKERS TO PREDICT TREATMENT RESPONSE
    Lynn Dressler; Fiscal Year: 2005
    ..is a laboratory companion to the clinical trial proposed by the CALGB, entitled," A Randomized Trial of Adjuvant Chemotherapy with Standard Regimens, Cyclophosphamide, Methotrexate and Fluorouracil- "CMF" or Cyclophosphamide and ..
  54. Fatigue & Breast Cancer-A Behavioral Sleep Intervention
    Ann Berger; Fiscal Year: 2006
    ..by applicant) Higher fatigue levels are found in women with stage I or II breast cancer receiving adjuvant chemotherapy (CT) who adopt patterns of daytime inactivity and nighttime restlessness and have more symptom and ..
  55. PRIMARY BREAST CANCER THERAPY GROUP (NSABP)
    Richard Margolese; Fiscal Year: 1980
    ..Patients have also been entered into adjuvant chemotherapy protocols, specifically Protocol #5:LPAM vs. Placebo #7:LPAM vs. LPAM & 5FU; #8:LPAM & 5FU vs...
  56. PRIMARY BREAST CANCER THERAPY GROUP
    Roger Poisson; Fiscal Year: 1991
    ..All patients undergo axillary dissection and those with histologically positive nodes receive adjuvant chemotherapy. This crucial protocol will tell us the clinical significance of multicentricity in breast cancer, the ..
  57. PRIMARY BREAST CANCER THERAPY GROUP
    Roger Poisson; Fiscal Year: 1980
    ..All patients undergo axillary dissection and those with histologically positive axillary nodes receive adjuvant chemotherapy. Thirteen (13) patients have also been entered in Protocol No...
  58. DIET--ENDOCRINE STUDY OF BREAST AND PROSTATE CANCER
    Wendy Demark Wahnefried; Fiscal Year: 1999
    ..The study is entitled "Exploration and Intervention in Weight Gain Associated with Adjuvant Chemotherapy for Breast Cancer...
  59. Magnetic Resonance Study of Chemotherapy-induced Liver Toxicity
    KRISTEN ZAKIAN; Fiscal Year: 2009
    ..patients who have previously undergone resection of Stage II or III colorectal cancer and who will undergo adjuvant chemotherapy. MR studies will be performed prior to the start of chemotherapy, and at 6 and 12-24 weeks after the ..
  60. BONE MARROW & SENTINEL NODE MICROMETASTASES IN BREAST CA
    Richard Cote; Fiscal Year: 2004
    ..identifies patients at increased risk of recurrence and death, and identifies the specific target of adjuvant chemotherapy. The specific aims are: (1) To identify and quantitate occult metastases in BM and SLN of patients with ..
  61. DETECTION AND PROGNOSIS OF GASTROINTESTINAL CANCER
    Samuel Ho; Fiscal Year: 2001
    ..Prognosis and patient selection for adjuvant chemotherapy are determined by pathological and clinical staging...
  62. BREAST CANCER SURVIVORS: EXERCISE AND RALOXIFENE
    Anna Schwartz; Fiscal Year: 2003
    ..The increasingly common use of adjuvant chemotherapy for breast cancer has led to a rise in long-term treatment- related side effects including osteoporosis, ..
  63. NURSING THERAPY--ATTENTIONAL FATIQUE IN CANCER PATIENTS
    Bernadine Cimprich; Fiscal Year: 2000
    ..breast cancer, who will be treated either with breast conserving surgery plus radiation or mastectomy plus adjuvant chemotherapy, will be randomly assigned to receive usual care or an experimental intervention; a home-based program of ..
  64. EVALUATION OF PRACTICE VARIATIONS AND COSTS FOR CANCER
    Sheldon Retchin; Fiscal Year: 1992
    ..of variations in the use of breast-conserving surgery for breast cancer; controversy over the use of adjuvant chemotherapy for breast and colorectal cancers; debate over the appropriate procedures for prostate cancer; and, ..
  65. MECHANISMS OF SURGICAL ADJUVANT INTRAVESICAL BCG
    Timothy Ratliff; Fiscal Year: 1991
    ..have shown that the efficacy of intravesical BCG as an adjuvant to surgery is superior to surgery alone or adjuvant chemotherapy. The mechanisms by which BCG mediates antitumor activity are not known...